MX2023006566A - Sistemas crispr tipo v clase 2 diseñados por ingeniería. - Google Patents

Sistemas crispr tipo v clase 2 diseñados por ingeniería.

Info

Publication number
MX2023006566A
MX2023006566A MX2023006566A MX2023006566A MX2023006566A MX 2023006566 A MX2023006566 A MX 2023006566A MX 2023006566 A MX2023006566 A MX 2023006566A MX 2023006566 A MX2023006566 A MX 2023006566A MX 2023006566 A MX2023006566 A MX 2023006566A
Authority
MX
Mexico
Prior art keywords
type
crispr systems
engineered class
engineered
class
Prior art date
Application number
MX2023006566A
Other languages
English (en)
Inventor
Benjamin Oakes
Sean Higgins
Sarah Denny
Brett T Staahl
Isabel Colin
Angus Sidore
Suraj Makhija
Gayathri Vijayakumar
Original Assignee
Scribe Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scribe Therapeutics Inc filed Critical Scribe Therapeutics Inc
Publication of MX2023006566A publication Critical patent/MX2023006566A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente descripción se proporcionan nucleasas tipo V clase 2, y ARN guías diseñados por ingeniería útiles para la edición de ácidos nucleicos diana. También se proporcionan métodos para elaborar y usar tales variantes para modificar ácidos nucleicos.
MX2023006566A 2020-12-03 2021-12-02 Sistemas crispr tipo v clase 2 diseñados por ingeniería. MX2023006566A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063121196P 2020-12-03 2020-12-03
US202163162346P 2021-03-17 2021-03-17
US202163208855P 2021-06-09 2021-06-09
PCT/US2021/061673 WO2022120095A1 (en) 2020-12-03 2021-12-02 Engineered class 2 type v crispr systems

Publications (1)

Publication Number Publication Date
MX2023006566A true MX2023006566A (es) 2023-08-07

Family

ID=80050633

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006566A MX2023006566A (es) 2020-12-03 2021-12-02 Sistemas crispr tipo v clase 2 diseñados por ingeniería.

Country Status (12)

Country Link
US (2) US20240026385A1 (es)
EP (1) EP4256054A1 (es)
JP (1) JP2023552374A (es)
KR (1) KR20230128289A (es)
AU (1) AU2021392719A1 (es)
CA (1) CA3201258A1 (es)
CL (1) CL2023001594A1 (es)
GB (1) GB2616584A (es)
MX (1) MX2023006566A (es)
PE (1) PE20231178A1 (es)
TW (1) TW202237836A (es)
WO (1) WO2022120095A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021015058A (es) 2019-06-07 2022-04-06 Scribe Therapeutics Inc Sistemas de casx artificiales.
WO2021113763A1 (en) 2019-12-06 2021-06-10 Scribe Therapeutics Inc. Compositions and methods for the targeting of rhodopsin
WO2022261150A2 (en) 2021-06-09 2022-12-15 Scribe Therapeutics Inc. Particle delivery systems
MX2024003455A (es) 2021-09-21 2024-04-03 Scribe Therapeutics Inc Sistemas de represores de casx dise?ados por ingenieria genetica.
TW202411426A (zh) 2022-06-02 2024-03-16 美商斯奎柏治療公司 經工程化的２類ｖ型ｃｒｉｓｐｒ系統
WO2023235888A2 (en) 2022-06-03 2023-12-07 Scribe Therapeutics Inc. COMPOSITIONS AND METHODS FOR CpG DEPLETION
WO2023240076A1 (en) 2022-06-07 2023-12-14 Scribe Therapeutics Inc. Compositions and methods for the targeting of pcsk9
WO2023240027A1 (en) 2022-06-07 2023-12-14 Scribe Therapeutics Inc. Particle delivery systems
WO2023240074A1 (en) 2022-06-07 2023-12-14 Scribe Therapeutics Inc. Compositions and methods for the targeting of pcsk9
WO2023240162A1 (en) 2022-06-08 2023-12-14 Scribe Therapeutics Inc. Aav vectors for gene editing
WO2023240157A2 (en) 2022-06-08 2023-12-14 Scribe Therapeutics Inc. Compositions and methods for the targeting of dmd
CN116676291B (zh) * 2022-08-22 2024-02-27 华中农业大学 核酸内切酶Genie scissor及其介导的基因编辑系统
WO2024206555A1 (en) 2023-03-29 2024-10-03 Scribe Therapeutics Inc. Compositions and methods for the targeting of pcsk9
WO2024206565A1 (en) 2023-03-29 2024-10-03 Scribe Therapeutics Inc. Repressor fusion protein systems
WO2024206676A1 (en) 2023-03-29 2024-10-03 Scribe Therapeutics Inc. Compositions and methods for the targeting of lpa
WO2024206620A1 (en) 2023-03-29 2024-10-03 Scribe Therapeutics Inc. Messenger rna encoding casx
JP7560818B1 (ja) 2023-08-25 2024-10-03 株式会社キュライオ エンジニアリングされたタンパク質

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5695937A (en) 1995-09-12 1997-12-09 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
WO2010075303A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
WO2012068627A1 (en) 2010-11-24 2012-05-31 The University Of Western Australia Peptides for the specific binding of rna targets
WO2017083722A1 (en) 2015-11-11 2017-05-18 Greenberg Kenneth P Crispr compositions and methods of using the same for gene therapy
EP3390624A4 (en) 2015-12-18 2019-07-10 The Regents of The University of California MODIFIED POLYPEPTIDES AND METHOD OF USE THEREOF
JP2019532644A (ja) * 2016-09-30 2019-11-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｒｎａ誘導型核酸修飾酵素及びその使用方法
WO2018195555A1 (en) 2017-04-21 2018-10-25 The Board Of Trustees Of The Leland Stanford Junior University Crispr/cas 9-mediated integration of polynucleotides by sequential homologous recombination of aav donor vectors
WO2019084148A1 (en) * 2017-10-25 2019-05-02 Monsanto Technology Llc TARGETED RNA GUIDED ENDONUCLEASE ENDONUCLEASE ACTIVITY IN EUKARYOTES
EP3841205A4 (en) * 2018-08-22 2022-08-17 The Regents of The University of California VARIANT TYPE CRISPR/CAS V EFFECTIVE POLYPEPTIDES AND METHODS OF USE THEREOF
MX2021015058A (es) 2019-06-07 2022-04-06 Scribe Therapeutics Inc Sistemas de casx artificiales.
WO2020247883A2 (en) 2019-06-07 2020-12-10 Scribe Therapeutics Inc. Deep mutational evolution of biomolecules
JP2023504536A (ja) 2019-12-06 2023-02-03 スクライブ・セラピューティクス・インコーポレイテッド 粒子送達システム
WO2021113769A1 (en) * 2019-12-07 2021-06-10 Scribe Therapeutics Inc. Compositions and methods for the targeting of htt
WO2021188729A1 (en) * 2020-03-18 2021-09-23 Scribe Therapeutics Inc. Compositions and methods for the targeting of c9orf72

Also Published As

Publication number Publication date
GB202309876D0 (en) 2023-08-16
TW202237836A (zh) 2022-10-01
GB2616584A (en) 2023-09-13
JP2023552374A (ja) 2023-12-15
CL2023001594A1 (es) 2024-01-05
AU2021392719A1 (en) 2023-06-22
US20230054437A1 (en) 2023-02-23
AU2021392719A9 (en) 2024-10-03
CA3201258A1 (en) 2022-06-09
EP4256054A1 (en) 2023-10-11
WO2022120095A1 (en) 2022-06-09
KR20230128289A (ko) 2023-09-04
PE20231178A1 (es) 2023-08-01
US20240026385A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
MX2023006566A (es) Sistemas crispr tipo v clase 2 diseñados por ingeniería.
WO2018209158A3 (en) CRISPR / RNA GUIDED NUCLEASE SYSTEMS AND METHODS
WO2018195545A3 (en) Variants of cpf1 (cas12a) with altered pam specificity
WO2019006471A3 (en) NOVEL CRISPR RNA TARGETING ENZYMES, SYSTEMS AND USES THEREOF
WO2023235818A3 (en) Engineered class 2 type v crispr systems
MX2022011460A (es) Composiciones y métodos para el direccionamiento de c9orf72.
EP4253551A3 (en) Novel crispr dna and rna targeting enzymes and systems
WO2018191715A3 (en) Polypeptides with type v crispr activity and uses thereof
MX2019015047A (es) Nucleasas guiadas por acidos nucleicos.
EP4361261A3 (en) Novel cas13b orthologues crispr enzymes and systems
PH12020550489A1 (en) Gene targets for nitrogen fixation targeting for improving plant traits
MX2020006072A (es) Métodos y composiciones relacionados con cpf1 para la edición genica.
PH12019502333A1 (en) Targeted compositions
MX2020011939A (es) Nuevas enzimas y sistemas crispr.
AU2018251801A8 (en) Novel type VI CRISPR orthologs and systems
WO2017180694A8 (en) Cas9 fusion molecules, gene editing systems, and methods of use thereof
EP3656873A3 (en) Polynucleotide enrichment and amplification using argonaute systems
MX2022011039A (es) Sistemas crispr clase ii tipo v.
MX2022007575A (es) Anticuerpos anti cumulo de diferenciacion 73 (cd73) y usos de estos.
SG10201805815YA (en) Rna-guided gene drives
MX2022012110A (es) Sistemas crispr clase ii tipo ii.
MX2023008629A (es) Nuevas nucleasas modificadas y quimericas.
MX2019006475A (es) Sistemas y métodos para dirección con arn guía puntual (arngp) de adn endógeno y fuente.
MY193486A (en) Novel 5 ' -inosinic acid dehydrogenase and method preparing 5'-inosinic acid using the same
ZA202202628B (en) Novel crispr dna targeting enzymes and systems